Request Demo
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2031260312 Durvalumab Adenocarcinoma of Esophagus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260312, evaluating Durvalumab in Adenocarcinoma of Esophagus: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07705555 Tiespectus Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07705555, evaluating Tiespectus in Diabetic macular oedema: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07704047 Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) Short Bowel Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07704047, evaluating Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) in Short Bowel Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and develop
Latest Hotspot
8 min read
NCT07704775 Nemolizumab Vulvar Lichen Sclerosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07704775, evaluating Nemolizumab in Vulvar Lichen Sclerosus: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07705568 EYS-611 Age Related Macular Degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07705568, evaluating EYS-611 in Age Related Macular Degeneration: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07704099 Rinvatercept Muscular Dystrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07704099, evaluating Rinvatercept in Muscular Dystrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07705607 Tiespectus Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07705607, evaluating Tiespectus in Diabetic macular oedema: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07704762 CONTROL ARM: Active-controlled Stress Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07704762, evaluating CONTROL ARM: Active-controlled in Stress Disorders: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262736 QLS-31905 Metastatic Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into CTR20262736, evaluating QLS-31905 in Metastatic Gastroesophageal Junction Adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
CTR20262733 Temozolomide Glioblastoma Multiforme Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into CTR20262733, evaluating Temozolomide in Glioblastoma Multiforme: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07707141 Prifemilast Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07707141, evaluating Prifemilast in Plaque psoriasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Soleno Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Soleno Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.